At a glance

At a glance
CSR report
Consolidated Key Figures

(thousands of €, if not stated otherwise)

Three months ended 31 March 2021

Three months ended 31 March 2020

Year ended 31 December 2020

Income Statement(*)

 

 

 

Revenues

113,892

94,817

478,053

Other income

10,266

8,743

52,207

R&D expenditure

(129,960)

(115,453)

(523,667)

S, G&A expenses

(44,996)

(34,325)

(185,225)

Operating expenses

(174,956)

(149,778)

(708,892)

Operating loss

(50,798)

(46,218)

(178,632)

Net financial results

38,125

(5,705)

(131,143)

Taxes

(157)

(336)

(1,226)

Net loss from continuing operations

(12,830)

(52,258)

(311,001)

Net profit from discontinued operations, net of tax

22,191

1,657

5,565

Net profit/loss (–)

9,361

(50,601)

(305,436)

 

 

 

 

Balance Sheet

 

 

 

Cash and cash equivalents

2,553,950

2,743,573

2,135,187

Current financial investments

2,560,743

2,978,805

3,026,278

R&D incentives receivables

142,304

115,240

135,728

Assets

5,615,059

5,992,406

5,717,731

Shareholders’ equity

2,701,462

2,840,041

2,670,355

Deferred income

2,698,417

2,913,398

2,809,133

Other liabilities

215,180

238,968

238,242

 

 

 

 

Cash Flow

 

 

 

Operational cash burn(**)

(127,669)

(83,398)

(517,404)

Cash flow used in operating activities

(121,209)

(68,874)

(427,336)

Cash flow generated from investing activities

499,859

929,640

757,288

Cash flow generated from financing activities

478

3,930

22,040

Increase in cash and cash equivalents

379,129

864,695

351,994

Effect of currency exchange rate fluctuation on cash and cash equivalents

31,750

17,261

(70,539)

Cash and cash equivalents at end of the period

2,553,950

2,743,573

2,143,071

 

 

 

Cash and cash equivalents from continuing operations

2,553,950

2,743,573

2,135,187

Cash and cash equivalents classified as assets held for sale

-

-

7,884

Current financial investments at the end of the period

2,560,743

2,978,805

3,026,278

Total current financial investments and cash and cash equivalents at the end of the period

5,114,693

5,722,378

5,169,349

 

 

 

 

Financial Ratios

 

 

 

Number of shares issued at end of the period

65,511,581

64,819,022

65,411,767

Basic income/loss (–) per share (in €)

0.14

(0.78)

(4.69)

Diluted income/loss (–) per share (in €)

0.14

(0.78)

(4.69)

Share price at end of the period (in €)

66.12

181.00

80.48

Total group employees at end of the period (number)(***)

1,328

1,130

1,489

(*)

The comparatives of 31 March 2020 have been restated to consider the impact of classifying the Fidelta business as discontinued operations in 2020.

(**)

We refer to the note on our cash position of our condensed consolidated interim financial statements for an explanation and reconciliation of this alternative performance measure.

(***)

The number of employees on 31 December 2020 and on 31 March 2020 included respectively 185 and 164 employees of Fidelta, which has been sold to Selvita on 4 January 2021.

Employees per site as of 31 March 2021

(total: 1,328 employees)

Employees per site as of 31 March 2021